




Indapamide–hypertension · 99.43% · DM




## Benazepril–hypertension · 99.38% · DM




Risedronate—osteoporosis · 99.36% · DM




## Metolazone-hypertension · 99.31% · DM




Chlorthalidone–hypertension · 99.31% · DM




## Eprosartan–hypertension · 99.28% · DM



## Nifedipine—hypertension · 99.24% · DM




# Bumetanide-hypertension · 99.23% · DM







# Pamidronate-osteoporosis · 99.23% · DM




Hydroflumethiazide—hypertension · 99.23% · DM




Amphetamine-obesity · 94.49% · nan





Bosutinib–lung cancer · 93.24% · nan




Tiagabine—epilepsy syndrome · 91.54% · NOT










Danazol–breast cancer · 89.03% · nan











Afatinib–lung cancer · 85.82% · nan

